Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109–2121. doi:10.1056/NEJMoa1616288
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi:10.1056/NEJMra1703413
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–1380. doi:10.1056/NEJMra0802714
   PubMed Web of Science ®Google Scholar
• Yu D, Zhao W, Vallega KA, Sun SY. Managing acquired resistance to third-generation EGFR tyrosine kinase inhibitors through co-targeting MEK/ERK signaling. Lung Cancer. 2021;12:1–10. doi:10.2147/LCTT.S293902
   PubMed Web of Science ®Google Scholar
• Shah R, Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations. Clin Lung Cancer. 2020;21(3):e216–e228. doi:10.1016/j.cllc.2019.12.003
   PubMed Web of Science ®Google Scholar
• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637–658. doi:10.1038/nrc.2017.84
   PubMed Web of Science ®Google Scholar
• Murtuza A, Bulbul A, Shen JP, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79(4):689–698. doi:10.1158/0008-5472.CAN-18-1281
   PubMed Web of Science ®Google Scholar
• Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020;38(25):2926–2936. doi:10.1200/JCO.19.03123
   Web of Science ®Google Scholar
• Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24(24):6195–6203. doi:10.1158/1078-0432.CCR-18-1542
   PubMed Web of Science ®Google Scholar
• Proto C, Lo Russo G, Corrao G, et al. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori. 2017;103(4):325–337. doi:10.5301/tj.5000663
   PubMed Web of Science ®Google Scholar
• Fang W, Ma Y, Yin JC, et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer. Clin Cancer Res. 2019;25(16):5015–5026. doi:10.1158/1078-0432.CCR-19-0585
   PubMed Web of Science ®Google Scholar
• Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262–269. doi:10.1038/nm.4040
   PubMed Web of Science ®Google Scholar
• Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi:10.1056/NEJMoa1411817
   PubMed Web of Science ®Google Scholar
• Sequist LV, Rolfe L, Allen AR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;373(6):578–579. doi:10.1056/NEJMc1506831
   PubMed Web of Science ®Google Scholar
• Sequist LV, Soria JC, Camidge DR. Update to rociletinib data with the recist confirmed response rate. N Engl J Med. 2016;374(23):2296–2297. doi:10.1056/NEJMc1602688
   PubMed Web of Science ®Google Scholar
• Bowcock AM. Invited review DNA copy number changes as diagnostic tools for lung cancer. Thorax. 2014;69(5):495–496. doi:10.1136/thoraxjnl-2013-204681
   PubMed Web of Science ®Google Scholar
• Liu L, Bai X, Wang J, et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across Metastatic Cancer. Clin Cancer Res. 2019;25(24):7413–7423. doi:10.1158/1078-0432.CCR-19-0558
   PubMed Web of Science ®Google Scholar
• Cosenza M, Krämer A. Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Res. 2016;24(1):105–126. doi:10.1007/s10577-015-9505-5
   PubMed Web of Science ®Google Scholar
• Xiang L, Fu X, Wang X, et al. A potential biomarker of combination of tumor mutation burden and copy number alteration for efficacy of Immunotherapy in KRAS-mutant advanced lung adenocarcinoma. Front Oncol. 2020;10:559896. doi:10.3389/fonc.2020.559896
   PubMed Web of Science ®Google Scholar
• Kachouie NN, Shutaywi M, Christiani DC. Discriminant analysis of lung cancer using nonlinear clustering of copy numbers. Cancer Invest. 2020;38(2):102–112. doi:10.1080/07357907.2020.1719501
   PubMed Web of Science ®Google Scholar
• Kuznetsova AY, Seget K, Moeller GK, et al. Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells. Cell Cycle. 2015;14(17):2810–2820. doi:10.1080/15384101.2015.1068482
   PubMed Web of Science ®Google Scholar
• Qiu M, Xia W, Chen R, et al. The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma. Cancer Res. 2018;78(11):2839–2851. doi:10.1158/0008-5472.CAN-17-2808
   PubMed Web of Science ®Google Scholar
• Dou T, Wang J, Han C, Shao X, Zhang J, Lu W. Cellular uptake and transport characteristics of chitosan modified nanoparticles in Caco-2 cell monolayers. Int J Biol Macromol. 2019;138(10):791–799. doi:10.1016/j.ijbiomac.2019.07.168
   PubMedGoogle Scholar
• Cheng Y, Ma L, Liu Y, et al. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors. Lung Cancer. 2020;145:63–70. doi:10.1016/j.lungcan.2020.04.004
   PubMed Web of Science ®Google Scholar
• Santoni-Rugiu E, Melchior L, Urbanska E, et al. EGFRIntrinsic resistance to EGFR-tyrosine kinase inhibitors in -mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers. 2019;11(7):923. doi:10.3390/cancers11070923
   PubMed Web of Science ®Google Scholar
• Kou F, Wu L, Ren X, Yang L. Chromosome abnormalities: new insights into their clinical significance in cancer. Mol Ther Oncolytics. 2020;17:562–570. doi:10.1016/j.omto.2020.05.010
   PubMed Web of Science ®Google Scholar
• Zhang VC, Wang J, Shao GG, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019;10(1):1772. doi:10.1038/s41467-019-09762-1
   PubMed Web of Science ®Google Scholar
• Chen H, Carrot-Zhang J, Zhao Y, et al. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun. 2019;10(1):5472. doi:10.1038/s41467-019-13460-3
   PubMed Web of Science ®Google Scholar
• Bao L, Zhang Y, Wang J, et al. Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. Cell Biol Toxicol. 2016;32(5):419–435. doi:10.1007/s10565-016-9343-z
   PubMed Web of Science ®Google Scholar
• Yuan S, Yu SL, Chen HY, et al. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J Clin Oncol. 2011;29(25):3435–3442. doi:10.1200/JCO.2011.35.3979
   PubMed Web of Science ®Google Scholar
• Zhu L, Liang J, Xia B, et al. Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer. J Thorac Dis. 2020;12(3):883–892. doi:10.21037/jtd.2019.12.97
   PubMed Web of Science ®Google Scholar
• Taylor AM, Shih J, Ha G, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676–689 e673. doi:10.1016/j.ccell.2018.03.007
   PubMed Web of Science ®Google Scholar
• Tan X, Banerjee P, Pham EA, et al. PI4KIIIbeta is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med. 2020;12(527). doi:10.1126/scitranslmed.aax3772
   Web of Science ®Google Scholar
• Micke P, Edlund K, Holmberg L, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1833–1840. doi:10.1097/JTO.0b013e3182295917
   PubMed Web of Science ®Google Scholar
• Hata T, Suenaga M, Marchionni L, et al. Genome-wide somatic copy number alterations and mutations in high-grade pancreatic intraepithelial neoplasia. Am J Pathol. 2018;188(7):1723–1733. doi:10.1016/j.ajpath.2018.03.012
   PubMed Web of Science ®Google Scholar
• Kaehler M, Osteresch P, Kunstner A, et al. Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models. Front Oncol. 2023;13:1200897. doi:10.3389/fonc.2023.1200897
   PubMed Web of Science ®Google Scholar
• Wang HL, Liu YC, Long MP, Zheng C, Yang JH. Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines. Oncol Lett. 2019;18(3):2977–2984. doi:10.3892/ol.2019.10643
   PubMed Web of Science ®Google Scholar
• Koba H, Kimura H, Yoneda T, et al. NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment. Transl Lung Cancer Res. 2021;10(11):4161–4173. doi:10.21037/tlcr-21-536
   PubMed Web of Science ®Google Scholar
• Morgillo F, Amendola G, Della Corte CM, et al. Dual MET and SMO negative modulators overcome resistance to EGFR inhibitors in human nonsmall cell lung cancer. J Med Chem. 2017;60(17):7447–7458. doi:10.1021/acs.jmedchem.7b00794
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang H, Wang J, et al. Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. Cancer Metastasis Rev. 2015;34(2):249–264. doi:10.1007/s10555-015-9558-0
   PubMed Web of Science ®Google Scholar
• Li G, Li W-R, Jin Y-G, Jie -Q-Q, Wang C-Y, Wu L. Tetrandrine attenuated doxorubicin-induced acute cardiac injury in mice. Biomed Res Int. 2020;2020(1):1–10.
   Google Scholar
• Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82–93. doi:10.1038/s41586-020-1969-6
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Schultz N, Gopalan A, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA. 2014;111(30):11139–11144. doi:10.1073/pnas.1411446111
   PubMed Web of Science ®Google Scholar
• Gerstung M, Jolly C, Leshchiner I, et al. The evolutionary history of 2658 cancers. Nature. 2020;578(7793):122–128. doi:10.1038/s41586-019-1907-7
   PubMed Web of Science ®Google Scholar
• Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322). doi:10.1126/science.aaf8399
   PubMed Web of Science ®Google Scholar